Wird geladen...

NCOA1–ALK: a novel ALK rearrangement in one lung adenocarcinoma patient responding to crizotinib treatment

The heterogeneity of ALK tyrosine-kinase inhibitor (TKI) responses poses a puzzling question to clinicians. Different variants of ALK rearrangements might be one of the mechanisms explaining this phenomenon. Therefore, identifying specific fusion forms is crucial to clinical practice. This case repo...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Onco Targets Ther
Hauptverfasser: Cao, Qi, Liu, Zhiguang, Huang, Yanhua, Qi, Chuang, Yin, Xiaowei
Format: Artigo
Sprache:Inglês
Veröffentlicht: Dove Medical Press 2019
Schlagworte:
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6369846/
https://ncbi.nlm.nih.gov/pubmed/30799936
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S192367
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!